EQUIFAX INC (EFX) Insider Transactions
Explore official ownership filings, with every record linked to its source.
EFX · EQUIFAX INC
How to read this data ↗View six-calendar-month insider history →
Recent reported activity
Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.
| Transaction / filed | Reporting owner(s) | Code / security | Quantity | Price as filed | Ownership | Source |
|---|---|---|---|---|---|---|
| 2026-11-09Filed 2026-11-12 | Farshchi JamilOfficer · EVP, Chief Technology OfficerFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/11/2026. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 510 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 15,110D | 189.77 | Direct | Form 4 ↗0001225208-26-008885 |
| 2026-10-30Filed 2026-11-02 | Schneider HaraldOfficer · EVP, Chief D&A OfficerFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. References: F1 | F WithholdingCommon Stock · Non-derivative | 689D | 184.6 | Direct | Form 4 ↗0001225208-26-008580 |
| 2026-10-29Filed 2026-11-02 | GAMBLE JOHN W JROfficer · EVP, CFO & COOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 5/28/2026. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 4,000D | 177.68 | Direct | Form 4 ↗0001225208-26-008579 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F6 | M Exercise / conversionStock Option/Right to Buy · Derivative | 37,792D | 0 | Direct | Form 4 ↗0001225208-26-008522 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F5, F2 | S Sale (market/private)Common Stock · Non-derivative | 33,667D | 182.517 | Direct | Form 4 ↗0001225208-26-008522 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F4, F2 | S Sale (market/private)Common Stock · Non-derivative | 1,681D | 185.2034 | Direct | Form 4 ↗0001225208-26-008522 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F2 | S Sale (market/private)Common Stock · Non-derivative | 1,250D | 183.403 | Direct | Form 4 ↗0001225208-26-008522 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F3, F2 | S Sale (market/private)Common Stock · Non-derivative | 1,194D | 186.7335 | Direct | Form 4 ↗0001225208-26-008522 |
| 2026-10-23Filed 2026-10-27 | Begor Mark WDirector · Officer · CEOFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 10/28/2025. F2 Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 226 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan. F3 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $186.6698 to $187.43, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F4 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $184.9466 to $185.5977, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F5 The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $181.7387 to $182.6225, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided. F6 The option vested in three equal annual increments beginning 5/4/2019. References: F1, F2 | M Exercise / conversionCommon Stock · Non-derivative | 37,792A | 112.46 | Direct | Form 4 ↗0001225208-26-008522 |
Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.